Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $309,616.80 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 5,451 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $56.80, for a total value of $309,616.80. Following the completion of the transaction, the insider now directly owns 165,881 shares in the company, valued at approximately $9,422,040.80. This represents a 3.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, June 17th, Soleil Boughton sold 2,572 shares of Hims & Hers Health stock. The stock was sold at an average price of $59.75, for a total transaction of $153,677.00.
• On Tuesday, May 27th, Soleil Boughton sold 3,233 shares of Hims & Hers Health stock. The shares were sold at an average price of $55.87, for a total transaction of $180,627.71.
• On Monday, April 28th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.19, for a total transaction of $97,694.84.
• On Monday, April 14th, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.72, for a total transaction of $92,937.92.
• On Monday, March 31st, Soleil Boughton sold 3,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.77, for a total value of $89,863.72.

Hims & Hers Health Stock Down 1.0%

NYSE:HIMS traded down $0.61 during mid-day trading on Tuesday, reaching $59.17. 35,141,346 shares of the company were exchanged, compared to its average volume of 21,323,036. The stock has a market cap of $13.24 billion, a PE ratio of 139.02, a PEG ratio of 2.25 and a beta of 2.09. Hims & Hers Health, Inc. has a 12 month low of $13.47 and a 12 month high of $72.98. The company has a fifty day moving average of $45.77 and a 200 day moving average of $38.46.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The business had revenue of $586.01 million for the quarter, compared to analysts' expectations of $535.21 million. During the same period in the prior year, the firm earned $0.05 earnings per share. Hims & Hers Health's revenue was up 110.7% compared to the same quarter last year. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HIMS shares. Morgan Stanley reissued an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a report on Wednesday, June 11th. TD Cowen cut shares of Hims & Hers Health from a "buy" rating to a "hold" rating and lowered their target price for the company from $44.00 to $30.00 in a research note on Tuesday, April 29th. Piper Sandler restated a "neutral" rating and set a $39.00 price target (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Bank of America lifted their price objective on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group raised their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has an average rating of "Hold" and a consensus target price of $38.00.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio bought a new stake in Hims & Hers Health during the 1st quarter worth about $1,469,000. Kilter Group LLC raised its stake in shares of Hims & Hers Health by 1.0% during the first quarter. Kilter Group LLC now owns 43,989 shares of the company's stock worth $1,300,000 after buying an additional 450 shares during the last quarter. Geneos Wealth Management Inc. acquired a new position in Hims & Hers Health in the first quarter valued at approximately $30,000. Intech Investment Management LLC boosted its stake in Hims & Hers Health by 74.5% in the first quarter. Intech Investment Management LLC now owns 143,287 shares of the company's stock valued at $4,234,000 after acquiring an additional 61,195 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Hims & Hers Health by 23.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after purchasing an additional 78,543 shares during the period. Institutional investors own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.